Business Context and Reporting Period
Syndax Pharmaceuticals, Inc. (SNDX) filed this Form 8-K on December 15, 2021, to report the entry into a material definitive agreement. The Company is a biopharmaceutical firm incorporated in Delaware with principal executive offices in Waltham, Massachusetts.
Key Financial Metrics and Transaction Details
This filing details a public equity offering rather than operational financial results. Key transaction metrics include:
- Securities Issued: 3,157,144 shares of Common Stock and pre-funded warrants to purchase 1,142,856 shares of Common Stock.
- Offering Price: $17.50 per share for Common Stock; $17.4999 per share for Pre-Funded Warrants.
- Expected Gross Proceeds: Approximately $75.3 million, or approximately $86.5 million if the underwriters' option is exercised in full.
- Underwriters' Option: An option to purchase up to an additional 645,000 shares of Common Stock.
- Expected Closing Date: On or about December 20, 2021.
The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes and Lock-Up Provisions
The primary material change is the dilution of existing shareholders due to the new issuance of equity and pre-funded warrants. To support the offering, the Company, its directors, executive officers, and certain stockholders have agreed to a 90-day lock-up period, prohibiting the sale or transfer of Common Stock without the written consent of the Representatives until March 15, 2022.
Outlook, Risks, and Contingencies
The offering is subject to customary closing conditions. The Pre-Funded Warrants include a beneficial ownership limitation, prohibiting exercise if the holder would own more than 9.99% of the outstanding Common Stock (extendable to 19.99% with notice). The Company is classified as an emerging growth company. No specific operational risks or guidance were detailed in this specific filing beyond the standard terms of the underwriting agreement.
Investor Verification Checklist
- Verify the final closing date and actual gross proceeds received upon the completion of the offering.
- Confirm whether the underwriters exercised their option to purchase the additional 645,000 shares.
- Review the Company's most recent 10-Q or 10-K for current cash position and burn rate to assess runway post-offering.
- Monitor the 90-day lock-up expiration date for potential selling pressure from insiders.